Background: The comparing the pancreaticojejunostomy with the pancreaticogastrostomy after pancreaticoduodenectomy operation in terms morbidity, pancreatic fistula and mortality. Patients and Methods: including retrospective 136 patients with diseases of the pancreas underwent pancreaticoduodenectomy operating at the Hue centre Hospital from January 2000 to anuary 2015. Results: morbidity rate of the pancreaticojejunostomy versus the pancreaticogastrostomy was (16%) and (15%). Numbers of patients of multiple compliations of the pancreaticojejunostomy group versus the pancreaticogastrostomy was 13 and 10. The pancreatic fistula and mortality rate of the pancreaticojejunostomy were (6.4%) and (1,3%), whereas those of the pancreaticogastrostomy were (5,0%) and (3,4%) respectively. Conclusions: there was no significant difference between the to groups with regard to pancreatic fistula, morbidity and mortality rate. key word: pancreaticoduodenectomy, pancreaticojejunostomy, pancreaticogastrostomy.

Introduction: To evaluate the feasibility and benefits of laparoscopic low anterior resection for upper and middle rectal cancer treatment. Material and method: Prospective study from 8/2013 to 8/2017 at Hue Central Hospital, a laparoscopic low anterior resection was performed in 45 patients with upper and mid rectal cancer. Result: There were 29 males and 16 females with the mean age of 60.3 ± 11.5 (range 38 – 75), no conversion, have three cases anastomotic leakage, the mortaliy rate was 0%. Mean follow-up duration 36 months: have tow cases local recurrence (4.4%), the overall survival rate was 100%. Conclusion: Laparoscopic low anterior resection for treatment upper and mid rectal cancer is safe and effective, initial results is good. Key words: upper and middle rectal cancer, Laparoscopic low anterior resection

Background: Hepatocellular carcinoma (HCC) is one of the most common cancer and ranks third in terms of cancer related deaths. The majority of patients are not eligible for curative treatment because of local or distal progression of tumor. RFA treatment following TACE has some advantages over TACE alone. The purpose of this study was to evaluate the effectiveness and survival benefits of the TACE+RFA approach to the management of unresectable HCCs in Hue Central Hospital, Vietnam. Methods: A prospective, cohort study on 60 patients, diagnosed with unresectable HCCs and treated with TACE combined with RFA at Hue Central Hospital from 1/2016 – 1/2019. All clinical and paraclinical data and adverse effects of each treatment, tumor response rate assessed by m-RECIST criteria, survival rate and other adverse events from the first treatment were documented. Results: There were no major complications after combined therapy except for two cases (1.4%) of liver failure treated successfully with conservative therapy. Tumor control rate (CR+PR) at three months after the last treatment was 81.6%. All patients were followed-up closely after treatment and additional treatments were decided based on imaging and laboratory results. The mean follow-up time was 19.3 (4 – 30) months. The 1-year and 2-year survival rates were 71.7% and 58.3%, respectively. Conclusion: Combination therapy with TACE and RFA is an effective, safe and feasible option for patients with unresectable HCCs. Key words: Hepatocellular carcinoma (HCC), transarterial chemoembolisation (TACE), radiofrequency ablation (RFA) 1